GNFTF (Genfit) Institutional Ownership : 0.86% (As of Apr. 02, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Genfit Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genfit's institutional ownership is 0.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genfit's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genfit's Float Percentage Of Total Shares Outstanding is 95.91%.

Genfit Institutional Ownership Historical Data

The historical data trend for Genfit's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Institutional Ownership Chart

Genfit Historical Data

The historical data trend for Genfit can be seen below:

	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28
Institutional Ownership	0.83	0.92	0.78	0.80	0.84	1.16	0.96	1.56	1.63	1.63

Genfit Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Genfit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

GNFT:USA 0QT6:UK GNFT:France XUPB:Germany XUPB:Germany XUP:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.